• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Initiator Pharma

2.86 SEK

+5.93 %

Less than 1K followers

INIT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+5.93 %
-2.72 %
-7.44 %
-3.38 %
-3.38 %
-26.10 %
-59.72 %
-48.76 %
-36.24 %

Initiator Pharma is a biotechnology company developing drug candidates for diseases of the central and peripheral nervous system. The company's main business focus is on the development of drug candidates used in the treatment of erectile dysfunction in men. Initiator Pharma was founded through a spin-off from the company Saniona and is headquartered in Denmark.

Read more
Market cap
195.78M SEK
Turnover
37.01K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
21/8
2026

Interim report Q2'26

20/11
2026

Interim report Q3'26

26/2
2027

Annual report '26

Press release2026-06-23 08:30

Initiator Pharma attends BIO 2026 in San Diego

Initiator Pharma
Press release2026-06-23 08:30

Initiator Pharma deltar vid BIO 2026 i San Diego

Initiator Pharma
Regulatory press release2026-05-29 11:55

Initiator Pharma A/S – Resolutions of the annual general meeting 2026

Initiator Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-05-12 10:00

Initiator Pharma A/S calls for the Annual General Meeting

Initiator Pharma
Press release2026-05-12 09:55

Remuneration report 2025 for Initiator Pharma A/S

Initiator Pharma
Press release2026-05-12 09:55

Ersättningsrapport 2025 för Initiator Pharma A/S

Initiator Pharma
Press release2026-05-11 10:00

DNB Carnegie Access: Initiator Pharma: Reassuring progress – Q1 review

Initiator Pharma
Regulatory press release2026-05-08 08:30

INITIATOR PHARMA: Q1 2026 REPORT

Initiator Pharma
Regulatory press release2026-05-08 08:30

INITIATOR PHARMA: RAPPORT FÖR FÖRSTA KVARTALET 2026

Initiator Pharma
Press release2026-04-29 10:31

DNB Carnegie Access: Initiator Pharma: Enrolment on track

Initiator Pharma
Press release2026-04-28 17:30

Initiator Pharma progresses patient enrollment in Phase 2a vulvodynia study

Initiator Pharma
Press release2026-04-28 17:30

Initiator Pharma rapporterar framsteg i patientrekryteringen till fas 2a-studie i vulvodyni

Initiator Pharma
Regulatory press release2026-04-28 11:00

Annual report 2025 for Initiator Pharma A/S

Initiator Pharma
Regulatory press release2026-04-28 11:00

Årsredovisning 2025 för Initiator Pharma A/S

Initiator Pharma
Press release2026-04-21 13:18

Redeye: Initiator Pharma: Full focus on pudafensine, IP2018 is discontinued

Initiator Pharma
Press release2026-04-17 12:31

DNB Carnegie Access: Initiator Pharma: All in on pudafensine

Initiator Pharma
Press release2026-04-17 08:30

Initiator Pharma to fully prioritize pudafensine

Initiator Pharma
Press release2026-04-17 08:30

Initiator Pharma fokuserar helt på pudafensine

Initiator Pharma
Press release2026-04-10 11:40

Initiator Pharma to present at Redeye Healthcare Day 2026

Initiator Pharma
Press release2026-04-10 11:40

Initiator Pharma presenterar vid Redeye Healthcare Day

Initiator Pharma